Manufacturing the Future: From N=1 Personalized CRISPR Therapy to Scalable Precision Genomic Medicine

Baby KJ’s landmark treatment, the first personalized mRNA base editing therapy for a life-threatening urea cycle disorder, demonstrated that precision gene editing can save a single life. But the true obligation of medicine is scale: transforming singular breakthroughs into solutions that can reach all who need them.

This scientific presentation and panel will explore the intellectual, technical, and translational journey from that Nof1 clinical triumph to a platform capable of treating many patients. Achieving this vision requires a new model of partnership, one grounded in platform thinking and shared innovation. Optimized process development frameworks, scalable manufacturing, advanced QC analytics, and modern regulatory paradigms must converge to convert bespoke interventions into reproducible, accessible, and cost-effective genetic medicines.

Learning Objectives:

Evolve one personalized mRNA base editing therapy into scalable, platform-driven solutions.
Leverage process, manufacturing, and QC innovation to ensure consistency and efficiency.
Algin partnerships and regulatory strategy to accelerate market readiness and access.